Association of Sars-Cov-2 Omicron Ba.1 on Adherence to Oral Tetrabenazine Congener and Quality of Life of Patients Diagnosed with Huntington's Disease with Chorea or Tardive Dyskinesia on the Service of a Usa Specialty Pharmacy

Author(s)

Burruss R1, Alhabashi R2, Arikian V3
1Burruss Pharmacy Consulting, Ashland, VA, USA, 2University of Maryland, Baltimore, MD, USA, 3SUNY Downstate Medical Center, Brooklyn, NY, USA

OBJECTIVES: During 1/1/-3/31/2022, SARS-CoV-2 Omicron BA.1 (CoVID-19 OBA.1) was pandemic in USA. Two study objectives are to determine if CoVID-19 OBA.1 was associated with a change in: (1) adherence to oral tetrabenazine analogue (TBZa) used to treat Huntington's Disease with chorea (HDc) or Tardive Dyskinesia (TDD) patients serviced by specialty pharmacy's medication therapy management program (SPMTM) and (2) patient-reported quality of life (QOL).

METHODS: A retrospective, observational, pre-/post-design study of HDc,TDD patient adherence to oral TBZa and associated QoL was conducted at beginning of and during CoVID-19 OBA.1 pandemic. Patient assessments (PA) occurred at start of care (SOC) and follow-up (F-U) 7 days before dispenses. PA included EQ-5D-5L QoL metrics. Descriptive statics used to calculate QoL dimensional means before and after starting TDZa and then on F-U SPMTM. Differences in means represented patient perceived changes in QoL. The medication possession ratio (MPR) was calculated using the F-U from both the Pre- and During-CoVID-19 OBA.1.

RESULTS: MPR = 0.96 prior to index time and was 0.93 During-CoVID-19 OBA.1 (3.1%). 238 PA were done During-CoVID-19 OBA.1 (280 HDc,TDD patients, 22 SOC, 250 F-U). Differences in QoL means Pre- vs During-CoVID-19 OBA.1 were: Mobility +0.0081 (0.81%), Self-Care +0.002 (0.2%), Usual Activities -0.0022 (0.22%), Pain/Discomfort -0.0103 (1.03%), Anxiety/Depression -0.0089 (0.89%), Overall Health State -0.07 (0.09%). Note: “-” = improvement; ”+”=worsened in Dimensions 1-5; “+” = improvement and ”-“ = worsened in Overall Health state. Percentages = absolute values.

CONCLUSIONS: MPR decreased by 3.1% compared to Pre-CoVID-19 OBA.1. Pre- and During-CoVID-19 OBA.1 MPR were higher than the industry standard of >0.9.5 On average, patients reported Mobility and Self-Care worsened but improved on Usual Activities, Pain/Discomfort and Anxiety/Depression dimensions of EQ-5D-5L. Over-all Health rating improved slightly by 0.09%. Explanations for worsened QoL metrics are discussed.7 Additional studies are suggested.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

PCR138

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance, Patient-reported Outcomes & Quality of Life Outcomes

Disease

SDC: Rare & Orphan Diseases, STA: Drugs

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×